“Reports have been emerging of a review of operations at GlaxoSmithKline and the possibility that the company might sell. There has also been talk of the possible effects this could have on the New Zealand blackcurrant industry. GSK currently purchase in the region of 40-45% of the national crop per year, for use in their Ribena branded drinks. Talk of a sale is pure speculation at the moment and the company say all options are open.”
To read the full article by Ben Littler please CLICK HERE to go to the FreshPlaza: Global Fresh Produce and Banana News.